Table of Contents
U.S. Health Care as % of GNP
Reasons for Cost Escalation
Financing of U.S. Health Care
Indemnity Insurance
Managed Care (HMOs)
Dichotomy of U.S. Health Care
HMO Enrollment in millions
Hospital Occupancy
Site of Medical Care
Growth of Physicians and Administrative Personnel
Health Care Inflation
Effects of Managed Care - I
Effects of Managed Care - II
Effects of Managed Care - III
Effects of Managed Care - IV
Effects of Managed Care - V
Ideas for Health Care Reform
Issues in Oncology - I
Issues in Oncology - II
Issues in Oncology - III
Issues in Oncology - IV
PPT Slide
PPT Slide
PPT Slide
PPT Slide
Common Cancers, 1998
Estimated Incidence, 1998
Estimated Deaths, 1998
Colorectal Cancer per 100,000
PPT Slide
Primary Prevention of Colorectal Cancer
Secondary Prevention of Colorectal Cancer - I
Secondary Prevention of Colorectal Cancer - II
Screening for Colon Cancer
Risks for Recurrence of Colorectal Cancer
Adjuvant Therapy Colon Cancer - I COG ‘81; NSABP
C-01 ‘88
Adjuvant Therapy - II Portal Vein Infusion - NSABP
C-02 ‘90
Adjuvant Therapy - IV Moertel ‘90,‘95
Adjuvant Therapy - III NSABP C-03 ‘93
Adjuvant Therapy - V NCCTG ‘97
Adjuvant Therapy - VI INT 0089 ‘98
Adjuvant Therapy for Colon Cancer Summary
Rectal Cancer NCCTG ‘94
Fluorouracil
Biomodulation of Fluorouracil - I
Biomodulation of Fluorouracil - II
Biomodulation of 5FU - III
PPT Slide
Methotrexate and 5FU Nordic GI Adj. Therapy Group
‘89
Trimetrexate and 5FU Vanderbilt ‘97
Interferon and 5FU Royal Marsden ‘95
Leucovorin and 5FU City of Hope ‘90
Leucovorin and 5FU Advanced Colorectal Meta-Analysis
Project ‘92
Infusional 5U - I Lokich ‘89
Infusional 5FU - II Meta-analysis Group in Cancer
‘98
Comparative 5FU Modulation - I NCCTG ‘89
PPT Slide
Comparative 5FU Modulation - II Mayo Clinic ‘91
Comparative 5FU Modulation - III SWOG ‘95
Comparative 5FU Modulation - IV de Gramont ‘97
Hepatic Artery Infusion MSKCC ‘94
New Agents in Colorectal Cancer
Camptosar - I
Camptosar - II Rougier ‘97
Camptosar - III European & MSKCC (pooled)
Oxaliplatin - I
Oxaliplatin - II Becouarn ‘97; Machover ‘96
Oxaliplatin and 5FU/LV de Gramont ‘98
Oxaliplatin with 5FU/LV Giachetti ‘97; Levi ‘94
5FU/LV and Oxaliplatin Levi ‘94
Raltitrexed - I
Raltitrexed - II Royal Melbourne ‘96
Uracil - Tegafur - I
Uracil-Tegafur - II MSKCC ‘95
Capecitabine
Summary: Advanced Colon Cancer
Future Directions in Colon Cancer |
Author: Dickerman Hollister, Jr., MD
Email:
Home Page:
Other information:
Albert Schweitzer Institute for the Humanities
Download presentation source |